血清转换盘显示接种mRNA-1273疫苗后抗SARS-CoV-2抗体产生
本研究分析了两组来自医护人员的COVID-19血清转换盘样本,采集于接种mRNA-1273疫苗(Moderna)前及第一剂和第二剂后,检测抗SARS-CoV-2 IgG抗体。接种前IgG阳性者第一剂后应答显著增强;年长受试者第一剂后免疫应答较低,第二剂后所有受试者抗SARS-CoV-2 IgG均为阳性。
要点
- 接种前抗SARS-CoV-2 IgG阳性者第一剂疫苗后应答显著增强。
- 年长受试者第一剂后免疫应答较低,第二剂后所有受试者IgG阳性。
核心结论
- 接种前抗SARS-CoV-2 IgG阳性者第一剂疫苗后应答显著增强;年长受试者第一剂后免疫应答较低,第二剂后所有受试者抗SARS-CoV-2 IgG均为阳性。
研究设计与样本
- 研究分析了两组来自医护人员的COVID-19血清转换盘样本,采集于接种mRNA-1273疫苗(Moderna)前及第一剂和第二剂后,检测抗SARS-CoV-2 IgG抗体。
主要发现
- 接种前抗SARS-CoV-2 IgG阳性的个体第一剂疫苗后应答显著增强。
- 年长受试者第一剂后免疫应答较低,第二剂后克服。
- 第二剂后所有受试者抗SARS-CoV-2 IgG均为阳性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Seroconversion panels are an important tool for investigating antibody responses in acute and chronic phases of disease and development of serological assays for viral diseases including COVID-19. Globally it is anticipated that vaccines against SARS-CoV-2 will facilitate control of the current pandemic. The two COVID-19 seroconversion panels analyzed in this study were obtained from healthcare workers with samples collected before vaccination with the mRNA-1273 vaccine (Moderna) and after the first and second doses of the vaccine. Panel samples were tested for antibodies to SARS-CoV-2 (IgG). Individual subjects with a positive response for anti-SARS-CoV2 IgG in their pre-vaccination samples showed a significantly enhanced response to the first vaccination. In older subjects, lower immunological responses to the first injection were observed, which were overcome by the second injection. All subjects in the study were positive for anti-SARS-CoV-2 IgG after the second dose of vaccine.
引用
- Belda F, Mora O, Lopez Martinez M, et al. Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine. Vaccine. 2022. PMID: 35443917. doi:10.1016/j.vaccine.2022.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。